Adverse reactions to positron-emitting radiopharmaceuticals

Silindir Günay M., Özölmez N.

JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, vol.333, no.12, pp.6093-6105, 2024 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 333 Issue: 12
  • Publication Date: 2024
  • Doi Number: 10.1007/s10967-024-09776-0
  • Journal Name: JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, Analytical Abstracts, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, Communication Abstracts, Food Science & Technology Abstracts, INSPEC, Metadex, Pollution Abstracts, Public Affairs Index, Veterinary Science Database, Civil Engineering Abstracts
  • Page Numbers: pp.6093-6105
  • Hacettepe University Affiliated: Yes

Abstract

Radiopharmaceuticals are medicinal products used for the diagnosis or treatment in nuclear medicine, consisting of a radioactive compound and generally a targeting pharmaceutical compound. Adverse drug reactions defined as harmful and unexpected responses that occur when administered at normal doses, have less severity and less incidence with radiopharmaceuticals than with conventional drugs. Though adverse reactions observed with positron-emitting radiopharmaceuticals are lesser and milder than both conventional drugs and other radiopharmaceuticals such as therapeutic and SPECT radiopharmaceuticals, adverse reactions that cannot be ignored still occur. Therefore, this review aims to raise awareness about adverse reactions observed in positron-emitting radiopharmaceuticals.